Which Peptides Does the 2026 WADA Prohibited List Actually Ban?

A research peptide does not become a doping agent by chemistry alone — it becomes one by appearing on a list. On 1 January 2026 the World Anti-Doping Agency’s Prohibited List came into force,¹ and for anyone who works with growth-hormone-adjacent peptides, the more interesting reading is not the long roll-call of banned molecules but the conspicuous gaps between the names.

What does Section S2 actually prohibit?

Section S2 — ‘Peptide Hormones, Growth Factors, Related Substances and Mimetics’ — is prohibited at all times,² meaning both in-competition and out-of-competition. That distinction matters: many substances are only barred during competition, but S2 follows the athlete year-round.² The section is also classified as non-specified, the category that attracts WADA’s strictest sanctions rather than the category that can attract reduced sanctions.

The list names its targets in unusually concrete terms. Among growth-hormone-releasing hormone (GHRH) analogues, it cites CJC-1293, CJC-1295, sermorelin and tesamorelin.¹ Among growth-hormone secretagogues (GHS) and mimetics, it names anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin.² A third cluster, the GH-releasing peptides (GHRPs), covers alexamorelin, examorelin (hexarelin), and GHRP-1 through GHRP-6, including pralmorelin (GHRP-2).¹ Finally, S2 reaches beyond secretagogues to growth factors and modulators themselves — IGF-1 and its analogues, mechano growth factors, VEGF and HGF.²

The level of enumeration is itself instructive. The list does not simply gesture at a class and trust readers to populate it; it spells out alexamorelin, examorelin and the full GHRP-1 through GHRP-6 series by name, and even pins down that pralmorelin is the same agent as GHRP-2.¹ That choice to name rather than rely solely on class language reduces the room for an athlete to argue that a particular GHRP fell outside the intended scope — the specificity does interpretive work that broad category headings alone would not.

Which catalogue compounds are explicitly named?

For a research catalogue, the overlap is specific and worth stating plainly. Four named substances appear directly: CJC-1295, sermorelin, tesamorelin and ipamorelin.¹ A fifth, IGF-1 LR3, is captured as an analogue of IGF-1, which S2 prohibits explicitly.² These are not borderline calls or interpretive stretches — they are written into the text of the list.

Catalogue overlap with WADA 2026 Section S2, distinguishing explicitly named substances from those not named but potentially captured by broader provisions.

1 Jan 2026 the date the WADA Prohibited List entered into force, with S2 prohibited at all times for athletes.

What about the compounds WADA does not name?

Here is where confident commentary tends to fail. BPC-157, TB-500 (thymosin-beta-4), MOTS-c and several other widely studied peptides are not explicitly named in S2. It is tempting to read that silence as permission. It is not.

Two provisions close the gap. The first is S0, WADA’s catch-all for any pharmacological substance not addressed by an approved-for-human-use regulatory authority and not otherwise on the list — a clause designed precisely to capture novel or unapproved compounds.¹ The second is the deliberately broad language of S2 itself, which prohibits not only named molecules but ‘mimetics’ and ‘related substances’, wording that can reach analogues and functionally similar agents²⁵ even where they are unnamed. So the honest position is neither ‘banned’ nor ‘allowed’: these compounds are not explicitly listed, yet remain capable of capture under S0 or the S2 mimetics clause.

The list’s silences are not loopholes. S0 and the ‘mimetics’ language exist so that an unnamed peptide is not, by default, a permitted one.

What does a WADA ban actually govern?

A point of frequent confusion is worth isolating. The Prohibited List regulates what athletes competing under the World Anti-Doping Code may have in their bodies. It is an instrument of sport, not a marketing-authorisation register, a controlled-substances schedule, or a verdict on a molecule’s status as laboratory material. These registers answer different questions and need not agree: a compound can be a licensed medicine in one register, an unapproved substance in another, and a prohibited doping agent in WADA’s — and its place in one tells you nothing automatic about its place in the others. A compound’s presence in S2 tells you it is prohibited for athlete use in competition and out of it; it tells you nothing about laboratory research conducted on that same substance as a characterised reference material.

That separation is the cleanest way to read the 2026 list without overstating it. WADA prohibition governs athlete use in sport — it does not govern bench research on a reference standard. Conflating the two produces exactly the kind of overstated claim the list itself does not make.

An honest appraisal of what remains uncertain

The named entries in S2 are unambiguous; the perimeter is not. Whether a specific unnamed peptide falls under S0 or the S2 mimetics clause in a given case is a determination that depends on facts WADA assesses,³⁴ not one a catalogue can settle in advance. Anyone who tells you BPC-157 or TB-500 is definitively ‘clean’ under the 2026 list³⁵ is reading past the catch-all provisions;⁴ anyone who tells you it is definitively banned is reading in a name that is not there. The accurate answer preserves the ambiguity rather than resolving it for rhetorical comfort.

Everything described here concerns research use only. The compounds referenced are characterised reference materials supplied for laboratory investigation — not approved medicines, not regulated therapeutics, and not products for human administration. A substance appearing in WADA’s Section S2 is, for athletes, a prohibited doping agent; the same molecule as a research-grade reference standard is a defined laboratory material and nothing more. The distinction between the regulated or approved article and the characterised reference material is the whole point, and we keep it intact.